IMBdx, a precision diagnostics provider, offers AlphaLiquid platform ctDNA-based testing across all cancer stages for patients, survivors, and high-risk individuals.
IMBdx operates as a precision diagnostics provider built around the AlphaLiquid platform, a liquid biopsy approach that analyzes trace ctDNA shed by tumor cells into body fluids instead of requiring a surgical tissue biopsy. The platform spans therapy selection, minimal residual disease monitoring, and multi-cancer early detection, collecting body fluids non-invasively. It delivers ctDNA-based precision diagnostics across all stages of cancer for patients, survivors, and high-risk individuals.
IMBdx relies on proprietary biochemistry for cfDNA extraction and library preparation. Its molecular diagnostic technology analyzes genomic alterations in cancer-related genes through an optimized laboratory and bioinformatic pipeline. ctDNA progression can precede radiological progression by a significant lead time.
